Reviewing Conatus Pharmaceuticals Inc. (CNAT)’s and OPKO Health Inc. (NASDAQ:OPK)’s results

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) and OPKO Health Inc. (NASDAQ:OPK) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Conatus Pharmaceuticals Inc. 33.59M 2.81 18.01M -0.61 0.00
OPKO Health Inc. 990.27M 1.50 153.04M -0.52 0.00

Table 1 highlights Conatus Pharmaceuticals Inc. and OPKO Health Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Conatus Pharmaceuticals Inc. -53.62% -84% -26%
OPKO Health Inc. -15.45% -16.4% -11.8%

Volatility & Risk

Conatus Pharmaceuticals Inc. has a 3.37 beta, while its volatility is 237.00%, thus making it more volatile than Standard & Poor’s 500. OPKO Health Inc. has a 1.89 beta and it is 89.00% more volatile than Standard & Poor’s 500.

Liquidity

Conatus Pharmaceuticals Inc. has a Current Ratio of 2.4 and a Quick Ratio of 2.4. Competitively, OPKO Health Inc.’s Current Ratio is 0.9 and has 0.8 Quick Ratio. Conatus Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than OPKO Health Inc.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Conatus Pharmaceuticals Inc. and OPKO Health Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Conatus Pharmaceuticals Inc. 0 1 1 2.50
OPKO Health Inc. 0 0 0 0.00

Conatus Pharmaceuticals Inc.’s upside potential is 110.53% at a $6 consensus target price.

Insider & Institutional Ownership

The shares of both Conatus Pharmaceuticals Inc. and OPKO Health Inc. are owned by institutional investors at 27.4% and 24.9% respectively. Insiders owned 3.66% of Conatus Pharmaceuticals Inc. shares. Competitively, 5.7% are OPKO Health Inc.’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Conatus Pharmaceuticals Inc. 12.37% -6.44% -53.91% -59.25% -58% 26.01%
OPKO Health Inc. -5.99% -27.45% -22.83% -54.36% -29.74% -11.3%

For the past year Conatus Pharmaceuticals Inc. has 26.01% stronger performance while OPKO Health Inc. has -11.3% weaker performance.

Summary

OPKO Health Inc. beats Conatus Pharmaceuticals Inc. on 6 of the 11 factors.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companyÂ’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.